Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot crossover pharmacokinetic study of JZP-324 formulations versus Xyrem in healthy adults
NL-OMON48951Completed
- Sponsor
- Jazz Pharmaceuticals plc
- Start
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of JZP324 and sodium oxybate in narcolepsy (3 arms), sponsored by Jazz Pharmaceuticals plc. Primary endpoints: Part 1 pharmacokinetics and relative bioavailability versus Xyrem, Part 2 pharmacokinetic profiles of 4 IR:MR formulations and 1 more. Started Sep 2017; status: completed.
02
Drugs
JZP324sodium oxybate
03
Conditions
narcolepsy
Beyond the preview
Go deeper on NL-OMON48951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48951.